Progress in the E7386 Phase II Clinical Trial and Clinical POC
First written in FY2024. 7 of 10 entries say "Advanced", first in FY2025-H1. Latest entry: 2026-10-09.
No other company in this theme has enough history to compare yet.
- FY2025AdvancedAnnual report
「Data presented at the European Society for Medical Oncology (ESMO) in October 2025 (data cutoff: 4 June 2025) showed an overall response rate of 36.7%, confirmed in 11 patients. The overall response rate was 57.1% among patients with no prior exposure to "Lenvima®."」
Enrollment of 30 patients in the E7386 combination trial with Lenvima was completed, with an overall response rate of 36.7% and a rate of 57.1% among patients with no prior exposure to Lenvima. Enrollment also began in the Phase II dose-optimization part. - FY2025-H1AdvancedAnnual report
「A Phase II part for patients with endometrial cancer is currently underway. Eisai has announced that it aims to obtain approval by March 2031 for the endometrial cancer indication in combination with "Lenvima®."」
The Phase II part of the E7386 program in endometrial cancer remains ongoing, and the partner has stated a target of obtaining approval by March 2031. - FY2024First statedAnnual report
「In November 2021, we achieved clinical proof of concept (POC) for this drug based on the results of multiple clinical trials.」
At ESMO in September 2024, interim analysis results from the endometrial cancer trial showed partial responses in 7 of 16 patients and stable disease in 4 patients.